PMID- 23238657
OWN - NLM
STAT- MEDLINE
DCOM- 20131202
LR  - 20211021
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Acute macrovascular dysfunction in patients with type 2 diabetes induced by 
      ingestion of advanced glycated beta-lactoglobulins.
PG  - 1278-82
LID - 10.2337/dc12-1489 [doi]
AB  - OBJECTIVE: Recent evidence indicates that heat-enhanced food advanced glycation 
      end products (AGEs) adversely affect vascular function. The aim of this study was 
      to examine the acute effects of an oral load of heat-treated, AGE-modified 
      beta-lactoglobulins (AGE-BLG) compared with heat-treated, nonglycated BLG (C-BLG) on 
      vascular function in patients with type 2 diabetes mellitus (T2DM). RESEARCH 
      DESIGN AND METHODS: In a double-blind, controlled, randomized, crossover study, 
      19 patients with T2DM received, on two different occasions, beverages containing 
      either AGE-BLG or C-BLG. We measured macrovascular [brachial ultrasound of 
      flow-mediated dilatation (FMD)] and microvascular (laser-Doppler measurements of 
      reactive hyperemia in the hand) functions at baseline (T0), 90 (T90), and 180 
      (T180) min. RESULTS: Following the AGE-BLG, FMD decreased at T90 by 80% from 
      baseline and remained decreased by 42% at T180 (P < 0.05 vs. baseline, P < 0.05 
      vs. C-BLG at T90). By comparison, following C-BLG, FMD decreased by 27% at T90 
      and 51% at T180 (P < 0.05 vs. baseline at T180). A significant decrease in 
      nitrite (T180) and nitrate (T90 and T180), as well as a significant increase in 
      N(epsilon)-carboxymethyllisine, accompanied intake of AGE-BLG. There was no change in 
      microvascular function caused by either beverage. CONCLUSIONS: In patients with 
      T2DM, acute oral administration of a single AGE-modified protein class 
      significantly though transiently impaired macrovascular function in concert with 
      decreased nitric oxide bioavailability. These AGE-related changes were 
      independent of heat treatment.
FAU - Stirban, Alin
AU  - Stirban A
AD  - Ruhr University Bochum, Bad Oeynhausen, Germany. alin.stirban@profil.com
FAU - Kotsi, Paraskevi
AU  - Kotsi P
FAU - Franke, Knut
AU  - Franke K
FAU - Strijowski, Ulf
AU  - Strijowski U
FAU - Cai, Weijing
AU  - Cai W
FAU - Gotting, Christian
AU  - Gotting C
FAU - Tschoepe, Diethelm
AU  - Tschoepe D
LA  - eng
SI  - ClinicalTrials.gov/NCT01456026
GR  - R01 DK091231/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20121213
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Lactoglobulins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*metabolism/*physiopathology
MH  - Female
MH  - Glycation End Products, Advanced/*adverse effects
MH  - Humans
MH  - Lactoglobulins/*adverse effects
MH  - Male
MH  - Microcirculation/drug effects
MH  - Middle Aged
PMC - PMC3631855
EDAT- 2012/12/15 06:00
MHDA- 2013/12/16 06:00
PMCR- 2014/05/01
CRDT- 2012/12/15 06:00
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2014/05/01 00:00 [pmc-release]
AID - dc12-1489 [pii]
AID - 1489 [pii]
AID - 10.2337/dc12-1489 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1278-82. doi: 10.2337/dc12-1489. Epub 2012 Dec 13.